XML 63 R30.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Consolidated Entities and Acquisitions (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Consolidated Entities and Acquisitions [Line Items] |
Pro Forma Information | The following table presents certain unaudited pro-forma financial information for the year ended December 31, 2022 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis’ common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.
|  | Year Ended December 31, |
(In thousands) |  | 2022 |
Revenue |  | $ | 357,880 |
Net income |  | $ | 204,987 |
Net income attributable to Innoviva stockholders |  | $ | 214,390 |
Entasis Therapeutics Holdings Inc |
Consolidated Entities and Acquisitions [Line Items] |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:
(In thousands) |  | February 17, 2022 |
Cash and cash equivalents |  | $ | 23,070 |
Prepaid expenses |  |  | 5,554 |
Other current assets |  |  | 1,959 |
Property and equipment, net |  |  | 185 |
Right-of-use assets |  |  | 959 |
Goodwill |  |  | 11,493 |
Intangible assets |  |  | 106,700 |
Other assets |  |  | 302 |
Total assets acquired |  | $ | 150,222 |
Accounts payable |  | $ | 1,583 |
Accrued personnel-related expenses |  |  | 1,058 |
Other accrued liabilities |  |  | 5,096 |
Deferred tax liabilities |  |  | 7,769 |
Total liabilities assumed |  | $ | 15,506 |
Total assets acquired, net |  | $ | 134,716 |
La Jolla Pharmaceutical Company |
Consolidated Entities and Acquisitions [Line Items] |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The following table represents the adjusted fair values of assets acquired and liabilities assumed by us in the transaction:
(In thousands) |  | August 22, 2022 |
Cash and cash equivalents |  | $ | 47,415 |
Short-term marketable securities |  |  | 471 |
Accounts receivable |  |  | 5,876 |
Inventory |  |  | 66,200 |
Prepaid expenses |  |  | 1,261 |
Other current assets |  |  | 907 |
Property and equipment, net |  |  | 13 |
Right-of-use assets |  |  | 226 |
Goodwill |  |  | 6,411 |
Intangible assets |  |  | 151,000 |
Deferred tax assets |  |  | 7,461 |
Other assets |  |  | 710 |
Total assets acquired |  | $ | 287,951 |
Accounts payable |  | $ | 1,237 |
Deferred revenue |  |  | 2,849 |
Other accrued liabilities |  |  | 11,362 |
Other long-term liabilities |  |  | 65,944 |
Total liabilities assumed |  | $ | 81,392 |
Total assets acquired, net |  | $ | 206,559 |
Theravance Respiratory Company, LLC |
Consolidated Entities and Acquisitions [Line Items] |
Summary of Financial Information of TRC |
(In thousands) |  |  |
Royalty revenue |  | $ | 72,029 |
Operating expenses |  |  | (332 | )
Income from operations |  |  | 71,697 |
Other income, net |  |  | 10 |
Realized loss |  |  | (39,386 | )
Income tax expense, net |  |  | 1 |
Changes in fair values of equity and long-term investments, net |  |  | (8,884 | )
Net income |  | $ | 23,438 |
ISP Fund LP |
Consolidated Entities and Acquisitions [Line Items] |
Summary of Individual Investments Held by ISP Fund | The following is a summary of individual investments held by ISP Fund at each balance sheet date:
|  | December 31, |
In thousands |  | 2024 |  |  | 2023 |
Common stock - Publicly traded healthcare companies |  |  |  |  |  |
United States |  | $ | 84,039 |  |  | $ | 184,926 |
United Kingdom |  |  | 1,989 |  |  |  | 2,942 |
Total common stock |  |  | 86,028 |  |  |  | 187,868 |
Preferred stock - Privately held healthcare companies |  |  |  |  |  |
United States |  |  | 53,591 |  |  |  | 52,530 |
Warrants - Privately held healthcare companies |  |  | 8,507 |  |  |  | 8,075 |
Money market fund and cash |  |  | 107,532 |  |  |  | 63,339 |
Total investments held by ISP Fund LP |  | $ | 255,658 |  |  | $ | 311,812 |

X
- Definition Consolidated entities and acquisitions. + References No definition available. + Details
Name: | inva_ConsolidatedEntitiesAndAcquisitionsLineItems
Namespace Prefix: | inva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of financial Information on consolidated entity. + References No definition available. + Details
Name: | inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock
Namespace Prefix: | inva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details
Name: | us-gaap_InvestmentTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |